Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;29(2):86-92.
doi: 10.1111/nep.14249. Epub 2023 Oct 21.

A pilot study of anti-nephrin antibodies in podocytopaties among adults

Natalia Chebotareva  1 , Anatoliy Vinogradov  2 , Yevgeniya Birukova  1 , Igor Alentov  3 , Natalia Sergeeva  3 , Daria Chemodanova  2 , Alexey S Kononikhin  4 , Sergey V Moiseev  1
Affiliations

A pilot study of anti-nephrin antibodies in podocytopaties among adults

Natalia Chebotareva et al. Nephrology (Carlton). 2024 Feb.

Abstract

Aim: Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are podocytopathies characterized by damage to the glomerular filtration barrier, leading to proteinuria and nephrotic syndrome. The production of anti-podocyte antibodies has been proposed as potential circulating factors contributing to the development of these conditions. The aim of the study is to evaluate the levels of anti-nephrin antibodies in patients with podocytopathies and healthy subjects.

Methods: In this study, a total of 77 patients with active glomerulopathy and 11 healthy subjects were included. Forty one patients were diagnosed with FSGS, 11 with MCD, and 25 with MN. To measure the levels of anti-nephrin antibodies, enzyme-linked immunosorbent assay was used.

Results: The levels of antibodies to nephrin were significantly higher in patients with MCD 61.2 [28.9-66.3] ng/mL and FSGS 32.5 [17.2-58.4] ng/mL compared to MN 20.3 [14.4-38.4] and healthy individuals 15.3 [12-18.9] ng/mL, p < .05. In patients with primary FSGS, the levels of antibodies to nephrin were significantly higher 45.2 [20-64.3] ng/mL compared to patients with secondary FSGS 26.7 [11.2-44.1] ng/mL, p < .05. There were no significant differences in the remission rate between the anti-nephrin antibodies positive and negative groups (log-rank test: p = .158).

Conclusion: The level of anti-nephrin antibodies was found to be significantly higher in patients with MCD and pFSGS compared to those with sFSGS, MN, and healthy subjects. Anti-nephrin antibodies in MCD and primary FSGS may be associated with the severity of podocytopathies, however they did not have an impact on the response to therapy.

Keywords: FSGS; MCD; anti-nephrin antibodies; nephrotic syndrome; podocytopathy.

PubMed Disclaimer

References

REFERENCES

    1. Hogg R, Middleton J, Vehaskari VM. Focal segmental glomerulosclerosis: epidemiology aspects in children and adults. Pediatr Nephrol. 2007;22(2):183-186. doi:10.1007/s00467-006-0370-5
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1-S276.
    1. Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017;12:502-517.
    1. De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC. Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach. J Am Soc Nephrol. 2018;29(3):759-774. doi:10.1681/ASN.2017090958
    1. Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996;334(14):878-883. doi:10.1056/NEJM199604043341402

Supplementary concepts

LinkOut - more resources